Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1891657

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1891657

Small Molecule Drug Discovery

PUBLISHED:
PAGES: 376 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Small Molecule Drug Discovery Market to Reach US$100.0 Billion by 2030

The global market for Small Molecule Drug Discovery estimated at US$61.5 Billion in the year 2024, is expected to reach US$100.0 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Oncology Therapeutic Area, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$38.9 Billion by the end of the analysis period. Growth in the Central Nervous Systems Therapeutic Area segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.5 Billion While China is Forecast to Grow at 10.0% CAGR

The Small Molecule Drug Discovery market in the U.S. is estimated at US$20.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.9 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Small Molecule Drug Discovery Market - Key Trends and Drivers Summarized

Why Is Small Molecule Drug Discovery Crucial for Modern Medicine?

Small molecule drug discovery is at the core of modern medicine as it focuses on developing therapeutics that can modulate specific biological pathways and targets to treat a wide range of diseases. Small molecules, typically low molecular weight compounds, have the advantage of being easily absorbed, distributed, metabolized, and excreted in the human body, making them ideal candidates for oral administration. These drugs play a crucial role in treating complex conditions such as cancer, cardiovascular diseases, neurological disorders, and infectious diseases. The growing emphasis on targeted therapies, personalized medicine, and the development of novel small molecule drugs for rare diseases and unmet medical needs is driving the demand for small molecule drug discovery.

How Are Technological Advancements Transforming Small Molecule Drug Discovery?

Technological advancements are transforming small molecule drug discovery by enhancing the efficiency, speed, and accuracy of the drug development process. The integration of high-throughput screening (HTS), computational drug design, and AI-driven predictive modeling is enabling researchers to identify potential drug candidates with high precision. The use of big data analytics and machine learning algorithms is revolutionizing the discovery process by analyzing large datasets and predicting drug-target interactions, toxicity, and efficacy. The emergence of fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) approaches is allowing for the identification of high-affinity compounds that can be optimized into potent therapeutics. These innovations are reducing the time, cost, and risk associated with drug development, fostering collaboration between pharmaceutical companies, research institutes, and contract research organizations (CROs).

Which Market Segments Are Driving the Adoption of Small Molecule Drug Discovery?

Therapeutic areas include oncology, neurology, immunology, cardiovascular, infectious diseases, and metabolic disorders, with oncology holding the largest market share due to the high prevalence of cancer and the demand for targeted therapies. Technologies encompass high-throughput screening, computational drug design, bioinformatics, and combinatorial chemistry, with high-throughput screening leading the market owing to its efficiency in screening large compound libraries. End-users include pharmaceutical and biotechnology companies, academic and research institutions, and CROs, with pharmaceutical companies being the primary adopters due to their focus on developing first-in-class and best-in-class therapeutics. Geographically, North America and Europe are the largest markets for small molecule drug discovery due to advanced healthcare infrastructure and significant R&D investments, while Asia-Pacific is emerging as a high-growth region driven by increasing healthcare expenditure and expanding biopharmaceutical industry.

What Are the Key Drivers of Growth in the Small Molecule Drug Discovery Market?

The growth in the small molecule drug discovery market is driven by several factors, including the rising focus on targeted therapies and personalized medicine, advancements in high-throughput screening, AI-based drug design, and computational drug discovery techniques. The increasing collaborations between pharmaceutical companies, research institutes, and CROs are driving market adoption for oncology, neurology, and immunology research. The growing demand for oral, small molecule therapeutics with improved bioavailability, safety, and efficacy profiles is expanding the market reach among diverse therapeutic areas. The surge in pipeline molecules, the expiration of key biologic patents, and the development of small molecule drug-drug conjugates (SMDCs) are creating new opportunities for market growth. Additionally, the rising investments in R&D for innovative drug discovery platforms, the adoption of fast-track and orphan drug designations, and the expansion of outsourcing drug discovery activities are further supporting market expansion.

SCOPE OF STUDY:

The report analyzes the Small Molecule Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Area (Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area, Other Therapeutic Areas); Process (Target ID / Validation Process, Lead Identification Process, Lead Optimization Process, Hit Generation & Selection Process); End-Use (Pharmaceutical Companies End-Use, Biotechnology Companies End-Use, Contract Research Organizations (CROs) End-use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 61 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP14780

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Small Molecule Drugs
    • The Evolving Future of Small Molecule Drugs
    • The Renaissance of Small Molecule Drug Discovery
    • Economic Frontiers: Trends, Trials & Transformations
    • In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2023 Through 2026
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Competitive Landscape
    • Small Molecule Drug Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Market Overview and Prospects
    • Global Small Molecule Drug Discovery Market Surges Ahead
    • A Glimpse of Big Segments of the Small Molecule Drug Discovery Market
    • Small Molecule Drugs Command Drug Type Category
    • High-Throughput Screening Rules Technology Segment
    • Target Identification & Validation Posts Notable Growth
    • Pharmaceutical Firms as Primary End-Users
    • The Supremacy of North America in Small Molecule Drug Discovery Market
    • Lucrative Avenues in Asia-Pacific
    • Small Molecules at Play: Drivers Shaping the Small Molecule Drug Discovery Market
    • Recent Market Activity
    • Domain Expert/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Pharma R&D Investments to Drive the Small Molecule Drug Discovery Market
    • Global Pharmaceutical R&D Spending in US$ Billion (2018-2026P)
    • Total Number of Registered Clinical Studies in'000s Worldwide (2012-2024)
    • Rise in Chronic Diseases Expands the Addressable Market Opportunity for Small Molecule Drug Discovery
    • As Disease Burden Rises so Does the Need for Medicines: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2024 and 2030
    • Rising Healthcare Expenditure Fuels Opportunities in Small Molecule Drug Discovery
    • World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021, 2023, 2025
    • Rising Focus on Targeted Therapies and Personalized Medicine Drives Small Molecule Drug Discovery Market
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • Late-Stage Drug Failures Drives Demand for Drug Discovery Technologies
    • Factors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others
    • Advancements in High-Throughput Screening (HTS) and Computational Drug Design Propel Market Innovation
    • Growth in Oncology, Neurology, and Immunology Research Expands Addressable Market for Small Molecule Drugs
    • Integration of AI, Machine Learning, and Big Data Analytics in Drug Discovery Accelerates Market Transformation
    • Emergence of Small Molecule Drug-Drug Conjugates (SMDCs) Expands Market Reach
    • Growing Use of Fragment-Based Drug Discovery (FBDD) and Structure-Based Drug Design (SBDD) Drives Adoption
    • Focus on Enhancing Target Selectivity, Efficacy, and Safety Profiles Sustains Market Growth
    • Surge in Pipeline Molecules and Expiry of Key Biologic Patents Drives Small Molecule Drug Development
    • The Rising Adoption of Cloud-Based Drug Discovery Platforms in Emerging Markets
    • Demand for Advanced Drug Discovery Platforms from CROs Set to Increase Rapidly
    • Global Contract Research Outsourcing Market Revenues (US$ Million) by Geographic Region/Country for 2020 and 2027
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Small Molecule Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Central Nervous Systems Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Central Nervous Systems Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Central Nervous Systems Therapeutic Area by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cardiovascular Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cardiovascular Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Cardiovascular Therapeutic Area by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Metabolic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Metabolic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Metabolic Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Respiratory Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Respiratory Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Respiratory Therapeutic Area by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Target ID / Validation Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Target ID / Validation Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Target ID / Validation Process by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Lead Identification Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Lead Identification Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Lead Identification Process by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Lead Optimization Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Lead Optimization Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Lead Optimization Process by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hit Generation & Selection Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hit Generation & Selection Process by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Hit Generation & Selection Process by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • JAPAN
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • CHINA
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • EUROPE
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • FRANCE
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • GERMANY
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of World 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Revenues for Oncology Therapeutic Area, Central Nervous Systems Therapeutic Area, Cardiovascular Therapeutic Area, Metabolic Disorders Therapeutic Area, Respiratory Therapeutic Area and Other Therapeutic Areas for the Years 2015, 2025 & 2030
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Small Molecule Drug Discovery by Process Phase - Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of World 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Revenues for Target ID / Validation Process, Lead Identification Process, Lead Optimization Process and Hit Generation & Selection Process for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!